ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 2146 - 2160 of 5996 products
Beijing Hengsheng Medical Completes $6 Million Funding for Coronary Devices
$5.00
Available
Ascletis Approved to Start China Trial of PD-L1 in HBV Patients
$5.00
Available
China Medical In-licenses China Rights to Novel Anemia Drug from Zydus Cadila
$5.00
Available
Oncologie Collaborates with Genialis to Identify Patients for Clinical Trials
$5.00
Available
Celltrion Plans $513 Million Wuhan Biologics Facility, 18 Biologic Launches in China by 2030
$5.00
Available
TenNor Receives Orphan Drug Designation in the US for Biofilm Infection Candidate
$5.00
Available
I-Mab Completes $104 Million IPO in the US for Biologics Portfolio
$5.00
Available
China-US Trade Agreement Specifies Patent Protection Rules for Drugs
$5.00
Available
WuXi Biologics Leases German Biologics Manufacturing Facility from Bayer
$5.00
Available
Tisenc Medical Raises $12 Million for Point-of-Care Chemiluminescence Testing
$5.00
Available
HitGen Collaborates with Kymera to Identify Protein Degradation Targets
$5.00
Available
BeiGene Announces $160 Million Agreement for China Rights to Two EUSA Orphan Biologics
$5.00
Available
Innovent Out-licenses US-Canada Rights for Avastin Biosimilar to Coherus In $45 Million Deal
$5.00
Available
Chi-Med Starts China Phase II Trial of Surufatinib/Tuoyi Combo in Solid Tumors
$5.00
Available
Sino Biopharma Signs Deal to Develop Two Novel Ambrx Biologics in China
$5.00
Available